Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (121-130 of 217) with videos related to

Pageof 22
Sort By:
Molecular Cancer|November 6, 2023
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluidCyril Roussel-Simonin, Felix Blanc-Durand, Roseline Tang, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Therapeutic Advances in Medical Oncology|December 30, 2025
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancersClaire Chator, Nozomu Yanaihara, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2023
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerFélix Blanc-Durand, Roseline Tang, Margaux Pommier, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2018
International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical CentersJennifer J Mueller, Henrik Lajer, Berit Jul Mosgaard, et al.
Oncoimmunology|March 28, 2017
Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i>-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitionFlorine A Eggink, Inge C Van Gool, Alexandra Leary, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 9, 2016
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancerInge C Van Gool, Ellen Stelloo, Remi A Nout, et al.
Oncotarget|December 17, 2017
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophagesHoucine Bougherara, Fariba Némati, André Nicolas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2015
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiativeEllen Stelloo, Tjalling Bosse, Remi A Nout, et al.
Pageof 22

Showing results (121-130 of 217) with videos related to

Sort By:
Pageof 22
Molecular Cancer|November 6, 2023
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluidCyril Roussel-Simonin, Felix Blanc-Durand, Roseline Tang, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Therapeutic Advances in Medical Oncology|December 30, 2025
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancersClaire Chator, Nozomu Yanaihara, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2023
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerFélix Blanc-Durand, Roseline Tang, Margaux Pommier, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2018
International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical CentersJennifer J Mueller, Henrik Lajer, Berit Jul Mosgaard, et al.
Oncoimmunology|March 28, 2017
Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i>-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitionFlorine A Eggink, Inge C Van Gool, Alexandra Leary, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 9, 2016
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancerInge C Van Gool, Ellen Stelloo, Remi A Nout, et al.
Oncotarget|December 17, 2017
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophagesHoucine Bougherara, Fariba Némati, André Nicolas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2015
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiativeEllen Stelloo, Tjalling Bosse, Remi A Nout, et al.
Pageof 22